Increased levels of inflammatory chemokines in amyotrophic lateral sclerosis

Kühle, Jens; Lindberg, Raija L. P.; Regeniter, Axel; Mehling, Matthias; Steck, Andrea; Kappos, L; Czapliński, Adam

doi:10.1111/j.1468-1331.2009.02560.x

Cited by 169 publications

(108 citation statements)

References 17 publications

Supporting

Mentioning

100

Contrasting

Unclassified

Order By: Relevance

“…Levels of IL-8 (and MCP-1) were considerably increased in cerebrospinal fluid (CSF) and serum from ALS patients compared to controls [23]. The expressions of both chemokines were higher in CSF relative to serum.…”

Section: Amyotrophic Lateral Sclerosis (Als)mentioning

confidence: 85%

Chemokine Interleukin-8 (IL-8) in Alzheimer’s and Other Neurodegenerative Diseases

McLarnon¹

2016

J Alzheimers Dis Parkinsonism

View full text Add to dashboard Cite

Section: Amyotrophic Lateral Sclerosis (Als)mentioning

confidence: 85%

Chemokine Interleukin-8 (IL-8) in Alzheimer’s and Other Neurodegenerative Diseases

McLarnon¹

2016

J Alzheimers Dis Parkinsonism

View full text Add to dashboard Cite

“…Some studies were limited by the number of samples in the analysis (Turner et al., 2013), and some chose a different control population into the study (Tateishi et al., 2010). In addition, a panel of biomarkers has been detected in either the CSF or serum in some recent studies, but they were either more concerned with a diagnosis rather than a clinically relevant prognosis (Gray et al., 2015; Kuhle et al., 2009; Lawton et al., 2012) or only measuring factors either the CSF or serum (Ehrhart et al., 2015; Mitchell et al., 2009). …”

Section: Introductionmentioning

confidence: 99%

Evaluating the levels of CSF and serum factors in ALS

et al. 2017

View full text Add to dashboard Cite

ObjectivesThe aim of this study was to identify CSF and serum factors as biomarkers that may aid in distinguishing ALS patients from control subjects and predicting ALS progression as well as prognosis.MethodsSerum and CSF samples from 105 patients with ALS and 56 control subjects were analyzed for 13 factors using ELISA. The revised ALS functional rating scale (ALSFRS‐r) was used to evaluate the overall functional status of ALS patients, and we also followed up with ALS patients either by phone or with clinic visits for five years after enrollment in this study. Finally, we examined the correlations between factor levels and various clinical parameters and evaluated the predictive value for prognosis through a multivariate statistic model.ResultsA total of eight factors were obviously elevated in CSF, and twelve markers were increased in serum. In the correlation analyses, there were trends toward higher bFGF, VEGF, MIP‐1α levels in ALS with a longer disease duration and slower disease progression in both CSF and serum. Higher MCP‐1 levels were associated with worse disease severity and faster progression, and the IFN‐γ levels were positively associated with disease progression in either CSF or serum. Finally, a better prognosis was observed with higher levels bFGF in CSF and VEGF in CSF and serum; conversely, patients with higher levels of IFN‐γ in the CSF had shorter overall survival.ConclusionsWe demonstrated that a factor profile of ALS patients is distinct from control subjects and may be useful in clinical practice and therapeutic trials.

show abstract

“…a p ϭ 0.016 compared to ⌬Z of patients predicted to have FTLD-tau by Student t test. MCP-1 was found by 2 previous studies 23,24 to be elevated in ALS, and MCP-1 was increased in our FTLD-TDP cases compared to control subjects ( p ϭ 0.01) and FTLD-tau ( p ϭ 0.089). However, MCP-1 did not emerge as a reliable biomarker for FTLD-TDP in the current study despite the difference in levels.…”

Section: Figure 1 Box Plots Showing Median Values Quartiles and Outmentioning

confidence: 66%

“…Other studies have also sought to identify biomarkers in disorders associated with FTLD, including ALS and progressive supranuclear palsy (PSP). Potential biomarkers of ALS have included elevated levels of TDP-43, 12 inflammatory proteins (GM-CSF, 23 G-CSF, 23 MCP-1, 23,24 MIP1a/b, 23 and multiple interleukins including IL-2, IL-6, IL-8, IL-15, and IL-17 23,24 ), axonal structural proteins (neurofilament light chain 25 ), and growth factors (FGF basic protein and VEGF 23 ), and decreased levels of cystatin C, 26 insulin-like growth factor 1, 27 IL-10, 23 interferon-␥, 23 erythropoietin, 28 and angiotensin II. 29 While alterations in some biomarkers are likely specific for FTLD-TDP spectrum disorders, changes in many likely can occur in either FTLD-TDP or FTLD-tau.…”

Section: Figure 1 Box Plots Showing Median Values Quartiles and Outmentioning

confidence: 99%

Novel CSF biomarkers for frontotemporal lobar degenerations

Chen‐Plotkin

Grossman³

et al. 2010

Neurology

View full text Add to dashboard Cite

Objective: To identify antemortem CSF diagnostic biomarkers that can potentially distinguish between the 2 main causes of frontotemporal lobar degeneration (FTLD), i.e., FTLD with TDP-43 pathology (FTLD-TDP) and FTLD with tau pathology (FTLD-tau).Methods: CSF samples were collected antemortem from 23 patients with FTLD with known pathology to form a autopsy cohort as part of a comparative biomarker study that additionally included 33 living cognitively normal subjects and 66 patients with autopsy-confirmed Alzheimer disease (AD). CSF samples were also collected from 80 living patients clinically diagnosed with frontotemporal dementia (FTD). Levels of 151 novel analytes were measured via a targeted multiplex panel enriched in neuropeptides, cytokines, and growth factors, along with levels of CSF biomarkers for AD.Results: CSF levels of multiple analytes differed between FTLD-TDP and FTLD-tau, including Fas, neuropeptides (agouti-related peptide and adrenocorticotropic hormone), and chemokines (IL-23, IL-17). Classification by random forest analysis achieved high sensitivity for FTLD-TDP (86%) with modest specificity (78%) in the autopsy cohort. When the classification algorithm was applied to a living FTD cohort, semantic dementia was the phenotype with the highest predicted proportion of FTLD-TDP. When living patients with behavioral variant FTD were examined in detail, those predicted to have FTLD-TDP demonstrated neuropsychological differences vs those predicted to have FTLD-tau in a pattern consistent with previously reported trends in autopsy-confirmed cases. Conclusions:Clinical cases with FTLD-TDP and FTLD-tau pathology can be potentially identified antemortem by assaying levels of specific analytes that are well-known and readily measurable in CSF. Neurology ® 2010;75:2079-2086 GLOSSARY AD ϭ Alzheimer disease; AgRP ϭ Aguti-related protein; ANG-2 ϭ angiopoietin-2; ACTH ϭ adrenocorticotropic hormone; ALS ϭ amyotrophic lateral sclerosis; ApoB ϭ apolipoprotein B; bv-FTD ϭ behavioral variant FTD; CBS ϭ corticobasal syndrome; FTD ϭ frontotemporal dementia; FTLD ϭ frontotemporal lobar degeneration; FTLD-tau ϭ frontotemporal lobar degeneration with tau pathology; FTLD-TDP ϭ frontotemporal lobar degeneration with TDP-43 pathology; IL ϭ interleukin; MDC ϭ macrophage-derived chemokine; PNFA ϭ progressive nonfluent aphasia; PPA ϭ primary progressive aphasia; PSP ϭ progressive supranuclear palsy; S100b ϭ S100 calcium binding protein b; SemD ϭ semantic dementia; TRAIL-R3 ϭ tumor necrosis factor-related apoptosis-inducing ligand receptor 3.Frontotemporal lobar degeneration (FTLD) includes neurodegenerative disorders which lead to progressive behavioral or language abnormalities.1-3 There are 2 major forms of FTLD: FTLD-TDP with neuronal and glial inclusions immunoreactive to TAR DNA binding protein of ϳ43 kD (TDP-43), and FTLD-tau containing fibrillar and hyperphosphorylated tau inclusions.2,3 The main FTLD lesions likely reflect distinct disease mechanisms, 2 although antemortem diagnosis of the underlying path...

show abstract

Increased levels of inflammatory chemokines in amyotrophic lateral sclerosis

Cited by 169 publications

References 17 publications

Chemokine Interleukin-8 (IL-8) in Alzheimer’s and Other Neurodegenerative Diseases

Chemokine Interleukin-8 (IL-8) in Alzheimer’s and Other Neurodegenerative Diseases

Evaluating the levels of CSF and serum factors in ALS

Novel CSF biomarkers for frontotemporal lobar degenerations

Contact Info

Product

Resources

About